[HTML][HTML] Sofosbuvir, velpatasvir, and voxilaprevir for previously treated HCV infection

…, SC Gordon, SL Flamm, CL Cooper… - … England Journal of …, 2017 - Mass Medical Soc
Background Patients who are chronically infected with hepatitis C virus (HCV) and who do
not have a sustained virologic response after treatment with regimens containing direct-acting …

Adherence to antiretroviral therapy in sub-Saharan Africa and North America: a meta-analysis

…, A Attaran, S Singh, B Rachlis, P Wu, C Cooper… - Jama, 2006 - jamanetwork.com
ContextAdherence to antiretroviral therapy is a powerful predictor of survival for individuals
living with human immunodeficiency virus (HIV) and AIDS. Concerns about incomplete …

[HTML][HTML] ABT-450/r–ombitasvir and dasabuvir with or without ribavirin for HCV

…, J Lalezari, D Cohen, Y Luo, C Cooper… - … England Journal of …, 2014 - Mass Medical Soc
Background The interferon-free regimen of ABT-450 with ritonavir (ABT-450/r), ombitasvir,
and dasabuvir with or without ribavirin has shown efficacy in inducing a sustained virologic …

[HTML][HTML] Life expectancy of HIV-positive individuals on combination antiretroviral therapy in Canada

…, W Zhang, J Raboud, AN Burchell, C Cooper… - BMC infectious …, 2015 - Springer
Background We sought to evaluate life expectancy and mortality of HIV-positive individuals
initiating combination antiretroviral therapy (ART) across Canada, and to consider the …

A map of the day–night contrast of the extrasolar planet HD 189733b

…, E Agol, NB Cowan, AP Showman, CS Cooper… - Nature, 2007 - nature.com
‘Hot Jupiter’ extrasolar planets are expected to be tidally locked because they are close (<0.05
astronomical units, where 1 au is the average Sun–Earth distance) to their parent stars, …

[HTML][HTML] Adherence to HAART: a systematic review of developed and developing nation patient-reported barriers and facilitators

…, P Wu, K Wilson, I Buchan, CJ Gill, C Cooper - PLoS …, 2006 - journals.plos.org
Background Adherence to highly active antiretroviral therapy (HAART) medication is the
greatest patient-enabled predictor of treatment success and mortality for those who have access …

[HTML][HTML] Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection

…, A Thompson, ML Shiffman, C Cooper… - … England Journal of …, 2015 - Mass Medical Soc
Background In phase 2 trials, treatment with the combination of the nucleotide polymerase
inhibitor sofosbuvir and the NS5A inhibitor velpatasvir resulted in high rates of sustained …

Life expectancy of persons receiving combination antiretroviral therapy in low-income countries: a cohort analysis from Uganda

…, J Birungi, K Chan, N Ford, CL Cooper… - Annals of internal …, 2011 - acpjournals.org
Background: Little is known about the effect of combination antiretroviral therapy (cART) on
life expectancy in sub-Saharan Africa. Objective: To estimate life expectancy of patients once …

A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel

…, A Alberti, E Bernasconi, M Buti, C Cooper… - Liver …, 2011 - Wiley Online Library
Background and Aim: Decisions on public health issues are dependent on reliable
epidemiological data. A comprehensive review of the literature was used to gather country‐specific …

[HTML][HTML] Ledipasvir and sofosbuvir for HCV in patients coinfected with HIV-1

S Naggie, C Cooper, M Saag… - … England Journal of …, 2015 - Mass Medical Soc
Background Effective treatment for hepatitis C virus (HCV) in patients coinfected with human
immunodeficiency virus type 1 (HIV-1) remains an unmet medical need. Methods We …